| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to information provided by health care providers and |
|
|
hospitals to certain patients regarding pharmaceutical |
|
|
manufacturer patient assistance programs for insulin. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Subchapter N, Chapter 531, Government Code, is |
|
|
amended by adding Section 531.509 to read as follows: |
|
|
Sec. 531.509. INFORMATION ON PHARMACEUTICAL MANUFACTURER |
|
|
PATIENT ASSISTANCE PROGRAMS FOR INSULIN. (a) This section applies |
|
|
to health care providers and hospitals that receive uncompensated |
|
|
care pool payments from the commission, including: |
|
|
(1) federally qualified health centers as defined by |
|
|
42 U.S.C. Section 1396d(l)(2)(B); |
|
|
(2) rural health clinics as defined by 42 U.S.C. |
|
|
Section 1396d(l)(1); and |
|
|
(3) physician group practices. |
|
|
(b) A health care provider or hospital to which this section |
|
|
applies shall provide to patients who have diabetes and require |
|
|
insulin information regarding the availability of pharmaceutical |
|
|
manufacturer patient assistance programs, including copay cards, |
|
|
that may reduce the cost of insulin to the patients. |
|
|
(c) The executive commissioner shall adopt rules to |
|
|
implement this section. |
|
|
SECTION 2. If before implementing any provision of this Act |
|
|
a state agency determines that a waiver or authorization from a |
|
|
federal agency is necessary for implementation of that provision, |
|
|
the agency affected by the provision shall request the waiver or |
|
|
authorization and may delay implementing that provision until the |
|
|
waiver or authorization is granted. |
|
|
SECTION 3. This Act takes effect September 1, 2021. |